Literature DB >> 18474609

S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.

Usha Narayanan1, Vijayalaxmi Nalavadi, Mika Nakamoto, George Thomas, Stephanie Ceman, Gary J Bassell, Stephen T Warren.   

Abstract

Fragile X syndrome is a common form of cognitive deficit caused by the functional absence of fragile X mental retardation protein (FMRP), a dendritic RNA-binding protein that represses translation of specific messages. Although FMRP is phosphorylated in a group I metabotropic glutamate receptor (mGluR) activity-dependent manner following brief protein phosphatase 2A (PP2A)-mediated dephosphorylation, the kinase regulating FMRP function in neuronal protein synthesis is unclear. Here we identify ribosomal protein S6 kinase (S6K1) as a major FMRP kinase in the mouse hippocampus, finding that activity-dependent phosphorylation of FMRP by S6K1 requires signaling inputs from mammalian target of rapamycin (mTOR), ERK1/2, and PP2A. Further, the loss of hippocampal S6K1 and the subsequent absence of phospho-FMRP mimic FMRP loss in the increased expression of SAPAP3, a synapse-associated FMRP target mRNA. Together these data reveal a S6K1-PP2A signaling module regulating FMRP function and place FMRP phosphorylation in the mGluR-triggered signaling cascade required for protein-synthesis-dependent synaptic plasticity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474609      PMCID: PMC2441545          DOI: 10.1074/jbc.C800055200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Distinct spatiotemporal expression of SAPAP transcripts in the developing rat brain: a novel dendritically localized mRNA.

Authors:  Stefan Kindler; Monika Rehbein; Bernhard Classen; Dietmar Richter; Tobias M Böckers
Journal:  Brain Res Mol Brain Res       Date:  2004-07-05

2.  Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression.

Authors:  Lingfei Hou; Eric Klann
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

3.  Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity.

Authors:  Marcia D Antion; Maayan Merhav; Charles A Hoeffer; Gerald Reis; Sara C Kozma; George Thomas; Erin M Schuman; Kobi Rosenblum; Eric Klann
Journal:  Learn Mem       Date:  2008-01-03       Impact factor: 2.460

4.  The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites.

Authors:  S Ferrari; R B Pearson; M Siegmann; S C Kozma; G Thomas
Journal:  J Biol Chem       Date:  1993-08-05       Impact factor: 5.157

5.  Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.

Authors:  Brian Raught; Franck Peiretti; Anne-Claude Gingras; Mark Livingstone; David Shahbazian; Greg L Mayeur; Roberto D Polakiewicz; Nahum Sonenberg; John W B Hershey
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

6.  Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver.

Authors:  H Flotow; G Thomas
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

7.  Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression.

Authors:  R M Mulkey; S Endo; S Shenolikar; R C Malenka
Journal:  Nature       Date:  1994-06-09       Impact factor: 49.962

8.  Epidermal growth factor-mediated activation of an S6 kinase in Swiss mouse 3T3 cells.

Authors:  I Novak-Hofer; G Thomas
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

9.  Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses.

Authors:  Laura N Antar; Rownak Afroz; Jason B Dictenberg; Reed C Carroll; Gary J Bassell
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

Review 10.  The mGluR theory of fragile X mental retardation.

Authors:  Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal:  Trends Neurosci       Date:  2004-07       Impact factor: 13.837

View more
  112 in total

1.  Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization.

Authors:  Hansen Wang; Susan S Kim; Min Zhuo
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Local RNA translation at the synapse and in disease.

Authors:  Liqun Liu-Yesucevitz; Gary J Bassell; Aaron D Gitler; Anne C Hart; Eric Klann; Joel D Richter; Stephen T Warren; Benjamin Wolozin
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 3.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 4.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

5.  Real-Time Imaging Reveals Properties of Glutamate-Induced Arc/Arg 3.1 Translation in Neuronal Dendrites.

Authors:  Youn Na; Sungjin Park; Changhee Lee; Dong-Kyu Kim; Joo Min Park; Shanthini Sockanathan; Richard L Huganir; Paul F Worley
Journal:  Neuron       Date:  2016-07-07       Impact factor: 17.173

Review 6.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 7.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

Review 8.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

9.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

Review 10.  Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

Authors:  Ken Inoki; Kun-Liang Guan
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.